Overview of computational methods employed in early-stage drug discovery

被引:7
|
作者
Skjevik, Age Aleksander [1 ]
Teigen, Knut [1 ]
Martinez, Aurora [1 ]
机构
[1] Univ Bergen, Dept Biomed, N-5009 Bergen, Norway
关键词
INTERACTION ENERGY METHOD; MOLECULAR-MECHANICS; STRUCTURAL GENOMICS; PERTURBATION METHOD; COMBINING DOCKING; SCORING FUNCTIONS; LIGAND DOCKING; BINDING; DESIGN; STATE;
D O I
10.4155/FMC.09.7
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Background: The understanding of biomolecular interactions ultimately depends on knowledge about the structural and dynamic details of the interacting system. Rational structure-based drug design implements computational methodology in this rationale. Discussion: Together with increasing throughput of structural biology, molecular modeling has progressively contributed to rational drug design and elucidation of nontoxic and patient-tailored interventions, helping to make drug development more cost-efficient. But in this challenging time for the pharmaceutical industry, the successful discovery of novel therapeutics should rely on integration of computational modeling with experimentation when it comes to ligand-binding energetics, system flexibility and genetic diversity/heterogeneity of the target. Moreover, it appears that many drugs even those for which specific receptors have been identified intercalate in biological membranes, which could also become the actual target. Conclusions: Understanding the drug-target and drug-unwanted-target interactions at the atomic level is fundamental in the initial phases of the drug development process. Molecular dynamics simulations and complementary computational methods are already contributing in this endeavor for the soluble pharmacological targets and show an increasing importance in the understanding of membrane-ligand interactions.
引用
收藏
页码:49 / 63
页数:15
相关论文
共 50 条
  • [31] Drug therapy in early-stage breast cancer
    Hara, F.
    ANNALS OF ONCOLOGY, 2024, 35 : S1306 - S1306
  • [32] Computational chemistry opportunities in early drug discovery
    Ruppel, Sabine
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2012, 244
  • [33] Biophysical methods in early drug discovery
    Holdgate, Geoffrey
    Embrey, Kevin
    Milbradt, Alexander
    Davies, Gareth
    ADMET AND DMPK, 2019, 7 (04): : 222 - 241
  • [34] DrugPose: benchmarking 3D generative methods for early stage drug discovery
    Jocys, Zygimantas
    Grundy, Joanna
    Farrahi, Katayoun
    DIGITAL DISCOVERY, 2024, 3 (07): : 1308 - 1318
  • [35] Rochester v. Searle: Complying with the written description and enablement requirements in early-stage drug discovery
    Brody, AY
    BIOTECHNOLOGY LAW REPORT, 2003, 22 (05) : 472 - 475
  • [36] Cytomyx' early-stage drug discovery services - Validation of novel targets for life-threatening diseases
    Pearson, S
    GENETIC ENGINEERING NEWS, 2002, 22 (05): : 62 - +
  • [37] Trends underlying early-stage drug discovery and development collaborations from October 2002 to September 2004
    Belsey, Mark J.
    Pavlou, Alex K.
    Journal of Commercial Biotechnology, 2005, 11 (04) : 369 - 373
  • [38] Discovery of piRNAs Pathway Associated with Early-Stage Spermatogenesis in Chicken
    Xu, Lu
    Qiu, Lingling
    Chang, Guobin
    Guo, Qixin
    Liu, Xiangping
    Bi, Yulin
    Zhang, Yu
    Wang, Hongzhi
    Li, Zhiteng
    Guo, Xiaoming
    Wan, Fang
    Zhang, Yang
    Xu, Qi
    Chen, Guohong
    PLOS ONE, 2016, 11 (04):
  • [39] Radiofrequency ablation of early-stage invasive breast tumors: An overview
    Singletary, SE
    Fornage, BD
    Sneige, N
    Ross, MI
    Simmons, R
    Giuliano, A
    Hansen, N
    Kuerer, HM
    Newman, LA
    Ames, FC
    Babiera, G
    Meric, F
    Hunt, KK
    Edeiken, B
    Mirza, AN
    CANCER JOURNAL, 2002, 8 (02): : 177 - 180
  • [40] Recent applications of computational methods to allosteric drug discovery
    Govindaraj, Rajiv Gandhi
    Thangapandian, Sundar
    Schauperl, Michael
    Denny, Rajiah Aldrin
    Diller, David J.
    FRONTIERS IN MOLECULAR BIOSCIENCES, 2023, 9